# Immunogenicity and Safety Study of Inactivated Split Influenza Vaccine' in Healthy Korean Male Subjects

> **NCT02111070** · PHASE1 · COMPLETED · sponsor: **Il-Yang Pharm. Co., Ltd.** · enrollment: 44 (actual)

## Conditions studied

- Healthy

## Interventions

- **BIOLOGICAL:** IL-YANG FLU Vaccine

## Key facts

- **NCT ID:** NCT02111070
- **Lead sponsor:** Il-Yang Pharm. Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-09
- **Primary completion:** 2012-10
- **Final completion:** 2012-10
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2014-04-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02111070

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02111070, "Immunogenicity and Safety Study of Inactivated Split Influenza Vaccine' in Healthy Korean Male Subjects". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02111070. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*